

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Henry Lardy, et al.  
Application No. : 09/675,323  
Filed : September 28, 2000  
Title : Therapeutic Treatment of Androgen Driven Conditions  
Examiner : Elli Peselev  
TC/A.U. : 1623

Docket No. : HOLISED.063A  
Customer No. : 26551  
Confirmation No. : 2363

---

COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450

## **TRANSMITTAL LETTER** **RESPONSE TO OFFICE ACTION**

Sir:

Transmitted herewith for filing by EFS-Web submission on February 22, 2007 is the following

- (X) Amendments and response to the non-final office action mailed on August 22, 2006;
- (X) Affidavit under 37 CFR. § 1.131;
- (X) Information Disclosure Statement Amendment under 37 CFR. § 1.97;

This transmittal letter also constitutes a petition for extension of time under 37 CRF §1.136(a) for three (3) months.

The Commissioner is hereby authorized to charge the small entity fees of \$525.00 for extension of time fee under 37 CFR § 1.17(a)(3), the \$180.00 fee under 37 CFR § 1.17(p) for submission of an IDS and any additional fees which may be required, now or in the future (except the issue fee), or credit any overpayment to **Deposit Account No. 501536**.

Please use **Customer No. 26,551** for the correspondence address.

/Angelo Castellino/

Angelo J. Castellino, Ph.D.  
Registration No. 52,707  
Hollis-Eden Pharmaceuticals, Inc.  
4435 Eastgate Mall, Suite 400  
San Diego, CA 92121